News | March 09, 2022
SII’s Covovax approved for 12-17 years age group
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
100% efficacy against severe Covid-19 disease and hospitalizations
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
This surpasses the number of approvals supported in 2020
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
Subscribe To Our Newsletter & Stay Updated
